Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 7, Issue 6, 2012, Pages 1032-1040

  Piperdi, Bilal ^a   Walsh, William V ^b   Bradley, Kendra ^b   Zhou, Zheng ^b   Bathini, Venu ^b   Hanrahan Boshes, Meredith ^b   Hutchinson, Lloyd ^b   Perez Soler, Roman ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Bevacizumab; Bortezomib; Metastatic non small cell lung cancer

Indexed keywords

ACICLOVIR; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; DEXAMETHASONE; ONDANSETRON;

ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOMAGNESEMIA; HYPONATREMIA; INFECTION; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; VOMITING;

EID: 84861332378     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31824de2fa     Document Type: Article

References (32)

1. Jemal A, Tiwari R, Murray T, et al. Cancer Statistics 2004. CA Cancer J Clin 2008;58:71-96.
2. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899-909
3. Schiller JH, Harrington D, Belani CP, et al.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98. (Pubitemid 34438899)
4. Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer. Oncology 2001;61 Suppl 1:3-13.
5. Investigator's Brochure Genentech. Recombinant Humanized Monoclonal Anti-VEGF Antibody (rhuMAb VEGF, Bevacizumab), 2005.
6. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550. (Pubitemid 44917502)
7. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-1234.
8. Di Costanzo F, Mazzoni F, Micol Mela M, et al. Bevacizumab in non-small cell lung cancer. Drugs 2008;68:737-746. (Pubitemid 351550528)
9. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-2622. (Pubitemid 29269108)
10. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638-2645. (Pubitemid 29437352)
11. Millennium Pharmaceuticals, Inc. VELCADE (bortezomib) (package insert). Cambridge, MA, 2011.
12. Investigator's Brochure Millennium Pharmaceuticals. VELCADE (bortezomib) for Injection (10th Edition), 2011.
13. Ling Y-H, Liebes L, Perez-Soler R, et al. Mechanism of proteasome inhibitor PS-341-induced G2-M-phase arrest and apoptosis in human NSCLC cell lines. Clin Cancer Res 2003;9:1145-1154. (Pubitemid 36323724)
14. Ling Y-H, Liebes L, Zou Y, et al. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem. 2003;278:33714-33723. (Pubitemid 37553204)
15. Mortenson M, Schlieman M, Virudachalam S, et al. Effect of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small cell lung cancer cell lines. Cancer Chemother Pharmacol 2004;54:343-353. (Pubitemid 39304429)
16. Ling Y-H, Liebes L, Perez-Soler R et al. PS-341, a novel proteasome inhibitor, induces bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 2002;1:841-849.
17. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-2511. (Pubitemid 34856332)
18. Li T, Ho L, Piperdi B, et al. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC). Lung Cancer 2010;68:89-93.
19. Kris MG, Johnson BE, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2011;29:(suppl; abstr CRA7506).
20. Fanucchi MP, Fossella FV, Belt R, et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5025-5033. (Pubitemid 46631406)
21. Davies AM, Chansky K, Lara PN Jr, et al.; Southwest Oncology Group. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol 2009;4:87-92.
22. Lynch TJ, Fenton D, Hirsh V, et al. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol 2009;4:1002-1009.
23. Scagliotti GV, Germonpré P, Bosquée L, et al. A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 2010;68:420-426.
24. Lara PN Jr, Longmate J, Reckamp K, et al. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer 2011;12:33-37.
25. Roccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006;66:184-191. (Pubitemid 43166024)
26. Belloni D, Veschini L, Foglieni C, et al. Bortezomib induces autophagic death in proliferating human endothelial cells. Exp Cell Res 2010;316:1010-1018.
27. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008;14:1407-1412. (Pubitemid 351413922)
28. An SJ, Huang YS, Chen ZH, et al. Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy. Med Oncol 2011.
29. Starlinger P, Maier T, Schauer D, et al. Brostjan Association of VEGF feedback production in bevacizumab therapy with systemic response. J Clin Oncol 2010;28:15s, (suppl; abstr 3056).
30. Falchook GS, Wheler JJ, Tannir NM, et al. Hypoxia-inducible factor-1α (HIF-1α) modulation in combination with anti-angiogenic therapy. J Clin Oncol 2008;26:(suppl; abstr 14604).
31. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10. (Pubitemid 19099520)
32. Therasse P, Arbuck S, et. al., Response Evaluation Criteria in solid Tumors (RECIST) Committee. New guidelines to evaluate the response to treatment in solid tumors. JNCI J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)